Lifestyle Delivery Systems Inc., CA53224Y1043

Lifestyle Delivery Systems Inc., CA53224Y1043

07.11.2018 - 14:43:14

Lifestyle Delivery Systems Inc. Announces Rêveur Corporation Revenue Increases in October Over Previous Month

Lifestyle Delivery Systems Inc. Announces Rêveur Corporation Revenue Increases in October Over Previous Month Vancouver, British Columbia, Canada, November 7, 2018, Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQX: LDSYF), (Frankfurt: LD6, WKN: A14XHT) ("LDS" or the "Company") announces that for the month ending October 31, 2018, Rêveur Corporation (formerly knows as CSPA Group, Inc.) recorded $1,171,389 (USD$900,376) in revenue from its Adelanto operations.

Rêveur Corporation continues to increase its revenue month over month, and the Company expects this trend to continue for the month of November 2018. LDS' CEO, Brad Eckenweiler, stated, "These revenue numbers are very encouraging and are possibly the best representation of the future outlook for the Adelanto facility." Mr. Eckenweiler continued by saying, "The ability for our shareholders to directly connect Rêveur Corporation revenue to LDS is beneficial for the Company and its shareholders, we are looking forward to our fourth quarter revenue results. Rêveur Corporation has generated over two million dollars in revenue to date." The Company will continue to update interested parties with respect to all operations of Rêveur Corporation.

About Rêveur Corporation Rêveur Corporation (formerly knows as CSPA Group, Inc.) is a wholly-owned subsidiary of Rêveur Holdings Inc., a wholly-owned subsidiary of LDS. Rêveur Corporation is located in Adelanto, California and is a City permitted and State Licensed manufacturer and distributor/transporter in the California cannabis industry manufacturing extracted oils and distillates, and producing CannaStripsTM under a license agreement with Lifestyle Delivery Systems Inc.About Lifestyle Delivery Systems Inc. Lifestyle Delivery Systems Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to any other form of delivery but also allows for inclusion of a wide spectrum of ingredients from over the counter medications to homeopathic, nutraceutical, vitamins and supplements. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. From start to finish, the production process, based on the Company's technology, tests for quality and composition of all the ingredients used in each and every strip which results in a delivery system that is safe, consistent and effective.

On behalf of the board of directors of Lifestyle Delivery Systems Inc.

Brad Eckenweiler CEO & Director Lifestyle Delivery Systems Inc.

Suite 820, 1130 W. Pender St. Vancouver BC, V6E 4A4 T: +1 (866) 347-5058 F: +1 (604) 648-0517

CSE : LDS

OTCQB : LDSYF

Frankfurt: LD6, WKN: A14XHT

www.lifestyledeliverysystem.com

FOR MORE INFORMATION, PLEASE CONTACT:investor.relations@lifestyledeliverysystem.com 1-866-347-5058

Cautionary Disclaimer Statement: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, The Company undertakes no obligation to publicly update or revise forward-looking information.

07.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

742491  07.11.2018 

@ dgap.de